Empower every individual with critical knowledge about their genetics, and gut microbiome and deliver convenient, personalized, and connected care so that they can live disease free
We are leading the digital GI space through innovation. First digital GI care company with three peer-reviewed studies demonstrating clinical efficacy across GI, mental health, and cardio-metabolic health. First GI care company with payer published efficacy data. First digital care company with Spanish and English Platform support. First GI solution that has FDA authorization and CDC Certification. First GI solution with support across the Americas, Asia & Europe. First GI solution contracted with Health Transformation Alliance - the largest pharma buying group for the F 200 employers. First GI solution with patented diagnostic and therapeutic signatures for GI.
GI disorders impact over 60M individuals and is the fastest-growing cost category for employers and payers because of poor diagnosis, fragmented care, poor outcomes, shortage of clinical talent, and the rising cost of biologics, urgent care, and ER visits.
n= 177. Demonstrated the proportion of subjects who experienced at least 20% improvement in symptom severity ranged from 75.32% for constipation to 90.63% for bloating 25% suffering from IBS became asymptomatic. Improvement in summative severity across the 6 FGIDs was seen by 89.42% of respondents, with an average summative reduction of 51.17% (Wilcoxon signed-rank test, P = <0.001). The improvement in FGID symptomatology over the course of the digital therapeutics intervention (percent summative reduction) was not correlated with percent weight loss. Conducted in partnership with Univ of San Diego Medical School. n = 369. More than 95% reported at least 20% improvement in at least one mental health condition - Anxiety, Depression, Sleep We found significant correlations between genetic scores with anxiety and depression at baseline, gut microbial functions with sleep problems at baseline, and genetic scores and gut microbial taxa and functions with anxiety, depression, and insomnia improvement. the abundance of kynurenine synthesis genes was associated with less than average improvement in anxiety symptoms, and the abundance of genes able to synthesize and degrade neuroactive hormones like nitric oxide was associated with greater than average improvement in depression and insomnia symptoms. We compared the relative ability of demographic, genetic, and microbiome factors to explain baseline and improvement in mental health and found that genetic and microbiome factors provide value above demographic variables alone. Medication and recreational drug use do not confound microbiome associations with mental health.
